- Home
- LAB vs LXRX Comparison
LAB vs LXRX Comparison
Compare LAB & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- LXRX
- Stock Information
- Founded
- LAB 1999
- LXRX 1995
- Country
- LAB United States
- LXRX United States
- Employees
- LAB 818
- LXRX N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- LAB Industrials
- LXRX Health Care
- Exchange
- LAB Nasdaq
- LXRX Nasdaq
- Market Cap
- LAB 504.2M
- LXRX 428.8M
- IPO Year
- LAB 2011
- LXRX 2000
- Fundamental
- Price
- LAB $1.30
- LXRX $1.52
- Analyst Decision
- LAB Buy
- LXRX Buy
- Analyst Count
- LAB 2
- LXRX 5
- Target Price
- LAB $2.50
- LXRX $3.23
- AVG Volume (30 Days)
- LAB 1.2M
- LXRX 2.6M
- Earning Date
- LAB 10-29-2025
- LXRX 11-11-2025
- Dividend Yield
- LAB N/A
- LXRX N/A
- EPS Growth
- LAB N/A
- LXRX N/A
- EPS
- LAB N/A
- LXRX N/A
- Revenue
- LAB $172,271,000.00
- LXRX $58,432,000.00
- Revenue This Year
- LAB N/A
- LXRX $67.21
- Revenue Next Year
- LAB N/A
- LXRX N/A
- P/E Ratio
- LAB N/A
- LXRX N/A
- Revenue Growth
- LAB 76.33
- LXRX 1504.83
- 52 Week Low
- LAB $0.92
- LXRX $0.28
- 52 Week High
- LAB $2.32
- LXRX $2.18
- Technical
- Relative Strength Index (RSI)
- LAB 48.53
- LXRX 70.28
- Support Level
- LAB $1.25
- LXRX $1.28
- Resistance Level
- LAB $1.38
- LXRX $1.42
- Average True Range (ATR)
- LAB 0.07
- LXRX 0.10
- MACD
- LAB -0.00
- LXRX 0.02
- Stochastic Oscillator
- LAB 26.83
- LXRX 81.00
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.